New! Sign up for our free email newsletter.
Science News
from research organizations

Novel therapy administered after TBI prevents brain damage

Treated mice had no seizures, which are common after brain trauma

Date:
July 16, 2019
Source:
University of Texas Health Science Center at San Antonio
Summary:
Could a therapy administered 30 minutes after a traumatic brain injury prevent damage that leads to seizures and other harmful effects? Researchers think so.
Share:
FULL STORY

An experimental treatment given to mice after a traumatic brain injury (TBI) reduced damage almost to the levels of mice that never had a TBI, researchers at UT Health San Antonio reported. The study was published July 4 in the Journal of Cerebral Blood Flow and Metabolism.

The scientists hope to convert the discovery into a simple and effective treatment for use in emergency rooms or by first responders shortly after a TBI has occurred in military and civilian settings. Currently, no treatment options exist for TBI patients.

"After a traumatic brain injury, about 40% of mice experience a seizure within one week, and many continue to experience seizures for years, leading to epilepsy disease," said study senior author Mark S. Shapiro, Ph.D., professor of cellular and integrative physiology at UT Health San Antonio. "This closely parallels what happens in human patients, followed by cognitive dysfunction and changes in emotional state."

Damaging effects

After a TBI, dangerous inflammation occurs throughout the brain, causing nerve cells to die and the blood-brain barrier, which is critical to maintaining normal brain function, to break down, said lead author Fabio A. Vigil, Ph.D., postdoctoral fellow in Dr. Shapiro's lab.

Preventing abnormal electrical activity

The novel therapy increases the activity of "M-type" KCNQ potassium ion channels, which are proteins that can halt uncontrolled electrical currents in nerve cells. Abnormal currents begin immediately after a TBI, even before a seizure has a chance to occur, and the therapy aims to counteract this, thus nipping in the bud this destructive chain of events.

"No seizures were observed in the treated mice whatsoever," Dr. Vigil said.

Neurologist's perspective

"We need treatments that alter some of the disabling consequences of TBI," said study co-author Jose E. Cavazos, M.D., Ph.D., a neurologist and epilepsy specialist at UT Health San Antonio. "Current antiseizure medications don't prevent the development of post-traumatic epilepsy. Our study examined this critically important therapeutic gap, and proposes a novel pharmacological intervention shortly after TBI that might prevent post-traumatic epilepsy."

If such a therapy can be developed, it would be a game-changer for patients, Dr. Cavazos said. Approximately 6% of all epilepsy cases are caused by head trauma.

"Think about the possibility of taking a medication shortly after the injury and preventing disabling epileptic seizures months to years later," Dr. Cavazos said.

Post-trauma impact

Study co-author Robert Brenner, Ph.D., of UT Health San Antonio, provided expertise in seizures and seizure monitoring. He said the study's most important finding is that reducing excess electrical activity in the central nervous system via a therapy such as this has beneficial post-trauma effects that extend well beyond action as an anticonvulsant. These effects include reducing dangerous inflammation and widespread cell death.

Ongoing and future research

This therapeutic approach is being evaluated for its suitability in humans, Dr. Shapiro said. This includes assessments of its chemical properties, stability, and effects on other organs such as the heart.

Future directions are to test newly developed compounds that have similar action to the compound used in this study, but with highly increased potency and selectivity for KCNQ potassium ion channels in the brain.


Story Source:

Materials provided by University of Texas Health Science Center at San Antonio. Note: Content may be edited for style and length.


Journal Reference:

  1. Fabio A Vigil, Eda Bozdemir, Vladislav Bugay, Sang H Chun, MaryAnn Hobbs, Isamar Sanchez, Shayne D Hastings, Rafael J Veraza, Deborah M Holstein, Shane M Sprague, Chase M Carver, Jose E Cavazos, Robert Brenner, James D Lechleiter, Mark S Shapiro. Prevention of brain damage after traumatic brain injury by pharmacological enhancement of KCNQ (Kv7, “M-type”) K currents in neurons. Journal of Cerebral Blood Flow & Metabolism, 2019; 0271678X1985781 DOI: 10.1177/0271678X19857818

Cite This Page:

University of Texas Health Science Center at San Antonio. "Novel therapy administered after TBI prevents brain damage." ScienceDaily. ScienceDaily, 16 July 2019. <www.sciencedaily.com/releases/2019/07/190716174105.htm>.
University of Texas Health Science Center at San Antonio. (2019, July 16). Novel therapy administered after TBI prevents brain damage. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2019/07/190716174105.htm
University of Texas Health Science Center at San Antonio. "Novel therapy administered after TBI prevents brain damage." ScienceDaily. www.sciencedaily.com/releases/2019/07/190716174105.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES